Author Archives: Steve Bryson PhD

Analysis: Uplizna Provides Long-term NMOSD Attack Prevention

Uplizna (inebilizumab-cdon) safely prevented autoimmune attacks in 83% of people with neuromyelitis optica spectrum disorder (NMOSD) who received the treatment for four or more years, data from the N-MOmentum Phase 2/3 clinical trial show. Among those who experienced relapses, most did so during the first year of treatment.

NMOSD Relapses Common, Increase Healthcare Costs in US

Almost half of U.S. patients with neuromyelitis optica spectrum disorder (NMOSD) experienced relapses over a period of two years, according to an analysis of a large healthcare claims database. Such relapses — which lasted on average nearly 13 days — were treated more often with outpatient rather than hospital…